From a theoretical pharmacological standpoint, combining a peptide with putative lipolytic activity (AOD 9604) with a potent triple incretin receptor agonist (retatrutide) could potentially amplify metabolic effects but this is speculative and raises the possibility of compounding adverse effects with no safety data to guide dosing or monitoring
Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85]
Slow, attentive eating and regular sleep patterns align with GLP-1's circadian rhythm
Le Minh, N., Damiola, F., Tronche, F., Schtz, G
Are there any lifestyle changes necessary for successful GLP-1 Therapy
Bains JS, Shaw CA